Literature DB >> 17056579

Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis.

Valérie Devauchelle1, Abdellatif Essabbani, Gonzague De Pinieux, Stéphane Germain, Léa Tourneur, Sylvie Mistou, Florence Margottin-Goguet, Philippe Anract, Henri Migaud, Dominique Le Nen, Thierry Lequerré, Alain Saraux, Maxime Dougados, Maxime Breban, Catherine Fournier, Gilles Chiocchia.   

Abstract

We previously compared by microarray analysis gene expression in rheumatoid arthritis (RA) and osteoarthritis (OA) tissues. Among the set of genes identified as a molecular signature of RA, clusterin (clu) was one of the most differentially expressed. In the present study we sought to assess the expression and the role of CLU (mRNA and protein) in the affected joints and in cultured fibroblast-like synoviocytes (FLS) and to determine its functional role. Quantitative RT-PCR, Northern blot, in situ hybridization, immunohistochemistry, and Western blot were used to specify and quantify the expression of CLU in ex vivo synovial tissue. In synovial tissue, the protein was predominantly expressed by synoviocytes and it was detected in synovial fluids. Both full-length and spliced isoform CLU mRNA levels of expression were lower in RA tissues compared with OA and healthy synovium. In synovium and in cultured FLS, the overexpression of CLU concerned all protein isoforms in OA whereas in RA, the intracellular forms of the protein were barely detectable. Transgenic overexpression of CLU in RA FLS promoted apoptosis within 24 h. We observed that CLU knockdown with small interfering RNA promoted IL-6 and IL-8 production. CLU interacted with phosphorylated IkappaBalpha. Differential expression of CLU by OA and RA FLS appeared to be an intrinsic property of the cells. Expression of intracellular isoforms of CLU is differentially regulated between OA and RA. We propose that in RA joints, high levels of extracellular CLU and low expression of intracellular CLU may enhance NF-kappaB activation and survival of the synoviocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056579     DOI: 10.4049/jimmunol.177.9.6471

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.

Authors:  Chung Hee Sonn; Young-Bin Yu; Young-Joo Hong; Young-Jun Shim; Jeffrey A Bluestone; Bon-Hong Min; Kyung-Mi Lee
Journal:  J Leukoc Biol       Date:  2010-08-20       Impact factor: 4.962

Review 2.  Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.

Authors:  Arturo Sala; Saverio Bettuzzi; Sabina Pucci; Olesya Chayka; Michael Dews; Andrei Thomas-Tikhonenko
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

3.  Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation.

Authors:  Shinwu Jeong; Dolena R Ledee; Gabriel M Gordon; Tatsuo Itakura; Nitin Patel; Aaron Martin; M Elizabeth Fini
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

4.  Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Authors:  Angela Lee; Yu Qiao; Galina Grigoriev; Janice Chen; Kyung-Hyun Park-Min; Sung Ho Park; Lionel B Ivashkiv; George D Kalliolias
Journal:  Arthritis Rheum       Date:  2013-04

5.  Identification of clusterin domain involved in NF-kappaB pathway regulation.

Authors:  Abdellatif Essabbani; Florence Margottin-Goguet; Gilles Chiocchia
Journal:  J Biol Chem       Date:  2009-12-22       Impact factor: 5.157

6.  Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA).

Authors:  Fan Zhang; Jian Sha; Thomas G Wood; Cristi L Galindo; Harold R Garner; Mark F Burkart; Giovanni Suarez; Johanna C Sierra; Stacy L Agar; Johnny W Peterson; Ashok K Chopra
Journal:  Cell Signal       Date:  2008-01-17       Impact factor: 4.315

7.  Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin.

Authors:  Soultana Markopoulou; Evangelos Kontargiris; Christina Batsi; Theodore Tzavaras; Ioannis Trougakos; David A Boothman; Efstathios S Gonos; Evangelos Kolettas
Journal:  FEBS J       Date:  2009-06-15       Impact factor: 5.542

8.  Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Authors:  Olesya Chayka; Daisy Corvetta; Michael Dews; Alessandro E Caccamo; Izabela Piotrowska; Giorgia Santilli; Sian Gibson; Neil J Sebire; Nourredine Himoudi; Michael D Hogarty; John Anderson; Saverio Bettuzzi; Andrei Thomas-Tikhonenko; Arturo Sala
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

9.  Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.

Authors:  Amina Zoubeidi; Susan Ettinger; Eliana Beraldi; Boris Hadaschik; Anousheh Zardan; Leo W J Klomp; Colleen C Nelson; Paul S Rennie; Martin E Gleave
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

10.  Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex.

Authors:  Ioannis P Trougakos; Magda Lourda; Marianna H Antonelou; Dimitris Kletsas; Vassilis G Gorgoulis; Issidora S Papassideri; Yonglong Zou; Lukas H Margaritis; David A Boothman; Efstathios S Gonos
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.